# Swiss Dermatology Network of Targeted Therapies (SDNTT)

> **NCT01706692** · — · RECRUITING · sponsor: **Swiss Dermatology Network for Targeted Therapies** · enrollment: 1121 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Adalimumab
- **BIOLOGICAL:** Etanercept
- **BIOLOGICAL:** Infliximab
- **BIOLOGICAL:** Ustekinumab
- **DRUG:** Cyclosporine A
- **DRUG:** Fumaric acids
- **DRUG:** Methotrexate
- **DRUG:** Other anti-psoriatic systemic treatments

## Key facts

- **NCT ID:** NCT01706692
- **Lead sponsor:** Swiss Dermatology Network for Targeted Therapies
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2011-02
- **Primary completion:** 2032-03-15
- **Final completion:** 2032-03-15
- **Target enrollment:** 1121 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706692, "Swiss Dermatology Network of Targeted Therapies (SDNTT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01706692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*